144 related articles for article (PubMed ID: 27801319)
1. [Analysis of the impact of decitabine treatment cycles on efficacy and safety in patients of myelodysplastic syndrome-refractory anemia with excess blasts].
Luo XP; Xu ZF; Qin TJ; Zhang Y; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Li B; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):870-875. PubMed ID: 27801319
[TBL] [Abstract][Full Text] [Related]
2. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
[TBL] [Abstract][Full Text] [Related]
3. [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Yang XL; Wu YM; Cao YB; Li XH; Xu LX; Liu ZY; Liu B; Yan B; Li SW; DA WM; Wu XX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):1056-61. PubMed ID: 26314446
[TBL] [Abstract][Full Text] [Related]
4. Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.
Salim O; Toptas T; Avsar E; Yucel OK; Ozturk E; Ferhanoglu B; Geduk A; Mehtap O; Tombak A; Tiftik EN; Deveci B; Kurtoglu E; Kara O; Atagunduz IK; Tuglular TF; Undar L
Leuk Res; 2016 Jun; 45():82-9. PubMed ID: 27107658
[TBL] [Abstract][Full Text] [Related]
5. Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.
Ye L; Ren Y; Zhou X; Mei C; Ma L; Ye X; Wei J; Xu W; Meng H; Qian W; Mai W; Lou Y; Xu G; Qian J; Lou Y; Luo Y; Xie L; Lin P; Hu C; Jin J; Tong H
J Cancer Res Clin Oncol; 2017 May; 143(5):873-882. PubMed ID: 28108816
[TBL] [Abstract][Full Text] [Related]
6. 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes.
Zagonel V; Lo Re G; Marotta G; Babare R; Sardeo G; Gattei V; De Angelis V; Monfardini S; Pinto A
Leukemia; 1993 May; 7 Suppl 1():30-5. PubMed ID: 7683354
[TBL] [Abstract][Full Text] [Related]
7. Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG).
Becker H; Suciu S; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Muus P; Pflüger KH; Hagemeijer A; Schaefer HE; Fiaccadori V; Baron F; Ganser A; Aul C; de Witte T; Wijermans PW; Lübbert M
Ann Hematol; 2015 Dec; 94(12):2003-13. PubMed ID: 26400023
[TBL] [Abstract][Full Text] [Related]
8. [The efficacy and safety of the patients of myelodysplastic syndromes-refractory anemia with excess blasts treated with decitabine alone or CAG/HAG regimen].
Xu ZF; Qin TJ; Zhang HL; Fang LW; Zhang Y; Pan LJ; Hu NB; Qu SQ; Li B; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):572-577. PubMed ID: 28810323
[No Abstract] [Full Text] [Related]
9. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.
Santini V; Fenaux P; Mufti GJ; Hellström-Lindberg E; Silverman LR; List A; Gore SD; Seymour JF; Backstrom J; Beach CL
Eur J Haematol; 2010 Aug; 85(2):130-8. PubMed ID: 20394651
[TBL] [Abstract][Full Text] [Related]
10. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
[TBL] [Abstract][Full Text] [Related]
11. Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy.
Ye L; Ren Y; Zhou X; Mei C; Xu W; Ma L; Luo Y; Hu C; Ye X; Wei J; Lou Y; Jin J; Tong H
Blood Cells Mol Dis; 2019 Jul; 77():88-94. PubMed ID: 31005752
[TBL] [Abstract][Full Text] [Related]
12. 5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.
Breccia M; Loglisci G; Salaroli A; Serrao A; Petrucci L; Mancini M; Alimena G
Leuk Lymphoma; 2012 Aug; 53(8):1558-60. PubMed ID: 22280532
[TBL] [Abstract][Full Text] [Related]
13. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.
Ribrag V; Suzan F; Ravoet C; Feremans W; Guerci A; Dreyfus F; Damaj G; Vantelon JM; Bourhis JH; Fenaux P
Leukemia; 2003 Feb; 17(2):319-22. PubMed ID: 12592329
[TBL] [Abstract][Full Text] [Related]
15. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
16. [Clinical Comparation of Two Kinds of Chemotherapy Regimens in the Treatment of Patients with MDS-RAEB/AML-MRC].
Wu XF; Li TT; Sun L; Wang LJ; Ran XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):894-898. PubMed ID: 32552954
[TBL] [Abstract][Full Text] [Related]
17. Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.
Panovska-Stavridis I; Ivanovski M; Trajkova S; Pivkova-Veljanovska A; Popova-Labaceska M; Matevska-Geshovska N; Noveski P; Plaseska-Karanfilska D; Cevreska L; Dimovski AJ
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Dec; 38(3):157-162. PubMed ID: 29668469
[TBL] [Abstract][Full Text] [Related]
18. Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.
Park H; Chung H; Lee J; Jang J; Kim Y; Kim SJ; Kim JS; Min YH; Cheong JW
Yonsei Med J; 2017 Jan; 58(1):35-42. PubMed ID: 27873493
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan.
Oki Y; Kondo Y; Yamamoto K; Ogura M; Kasai M; Kobayashi Y; Watanabe T; Uike N; Ohyashiki K; Okamoto S; Ohnishi K; Tomita A; Miyazaki Y; Tohyama K; Mukai HY; Hotta T; Tomonaga M
Cancer Sci; 2012 Oct; 103(10):1839-47. PubMed ID: 22816487
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts.
Serin I; Eren R; Dogu MH
J Hematol; 2020 Apr; 9(1-2):33-36. PubMed ID: 32362984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
